Table 1. Characteristics of the multiple myeloma patients at diagnosis.
| Multiple myeloma |
Reference range (male / female) |
|
|---|---|---|
| Number of patients | 20 | |
| Age, years | 70 ± 10 | |
| Male percentage | 55% | |
| ISS stage | ||
| I | 2 (10%) | |
| II | 7 (35%) | |
| III | 11 (55%) | |
| M-protein, g/L | 41.5 ± 19.9 | |
| IgG, n | 14 (70%) | |
| kappa | 11 (55%) | |
| lambda | 3 (15%) | |
| IgA, n | 6 (30%) | |
| kappa | 4 (20%) | |
| lambda | 2 (10%) | |
| INR | 1.1 ± 0.2 | <1.3 |
| APTT, s | 30 ± 4 | 25–40 |
| Fibrinogen, μmol/L | 9.4 ± 3.3 | 5.0–12.0 |
| D-dimer, mg/L | 0.80 ± 0.27 | <0.30 |
| Antithrombin, ×E9 IU/L | 0.88 ± 0.17 | 0.80–1.20 |
| Factor VIII, U/mL | 1.60 ± 0.73 | 0.60–1.60 |
| Protein C, U/mL | 1.10 ± 0.39 | 0.70–1.40 |
| Creatinine, μmol/L | 89 ± 23 / 77 ± 23 |
60–105 / 45–90 |
| Carbamide, mmol/L | 7.0 ± 2.6 / 6.2 ± 1.2 |
3.5–8.1 / 3.1–7.9 |
| Pt-estimated GFR, mL/min | 74 ± 17 | >60 |
| κ-chain, free, mg/L | 1153.1 ± 3723.9 | 3.3–19.4 |
| λ-chain, free, mg/L | 299.8 ± 697.1 | 5.7–26.3 |
| Calcium, mmol/L | 2.48 ± 0.15 | 2.20–2.55 |
| CRP, mg/L | 7.5 ± 22.7 | <8.0 |
| Albumin, g/L | 30 ± 4 | 34–45 |
| Protein, g/L | 106 ± 18 | 62–78 |
| ALAT, U/L | 23 ± 10 | 10–50 |
| Haemoglobin, mmol/L | 6.7 ± 1.5 / 6.0 ± 0.6 |
8.3–10.5 / 7.3–9.5 |
| Erythrocytes, ×E12/L | 3.44 ± 0.80 / 3.18 ± 0.38 |
4.30–5.70 / 3.90–5.20 |
| Platelets, ×E9/L | 198 ± 57 / 248 ± 52 |
145–350 / 165–400 |
| Leukocytes, ×E9/L | 6.3 ± 2.2 | 3.5–10.0 |
ISS = international staging system; IgG = immunoglobulin G; IgA = immunoglobulin A; INR = international normalized ratio; APTT = activated partial thromboplastin time; GFR = glomerular filtration rate; CRP = C-reactive protein; ALAT = alanine transaminase.